Algunas Inc., dba Woodland Hills Compounding Pharmacy FDA Wa
Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on July 17, 2017
Executive Summary
The FDA issued a warning letter to Algunas Inc., dba Woodland Hills Compounding Pharmacy on July 17, 2017 citing regulatory violations. The letter was issued by Los Angeles District Office.
Detailed Analysis
False Claims and Regulatory Violations
Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).
Potential Health Risks
Consumers should be aware of potential risks associated with products from Algunas Inc., dba Woodland Hills Compounding Pharmacy.
Regulatory Context
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).
Key Entities Identified
Frequently Asked Questions
- What did the FDA find wrong with Algunas Inc., dba Woodland Hills Compounding Pharmacy?
- The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.
- Are Algunas Inc., dba Woodland Hills Compounding Pharmacy products safe to use?
- Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.
- What should I do if I've used Algunas Inc., dba Woodland Hills Compounding Pharmacy products?
- If you have used products from Algunas Inc., dba Woodland Hills Compounding Pharmacy and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.
Source Document
This report is based on an official FDA warning letter. The original document is a public record.
View Original FDA Warning Letter